Previous 10 | Next 10 |
Silence to receive $3 million research milestone payment from Mallinckrodt Phase 1 study expected to begin in the first half of 2022 Silence Therapeutics plc (Nasdaq: SLN), a leader in the discovery, development and delivery of novel short interfering ribonucleic aci...
Silence Therapeutics plc (SLN) Q4 2021 Earnings Conference Call March 17, 2022 08:00 AM ET Company Participants Gem Hopkins - Head of Investor Relations and Corporate Communications Craig Tooman - President and Chief Executive Officer Rhonda Hellums - Chief Financial Officer Giles Campion - H...
The following slide deck was published by Silence Therapeutics plc in conjunction with their 2021 Q4 earnings call. For further details see: Silence Therapeutics plc 2021 Q4 - Results - Earnings Call Presentation
Silence Therapeutics press release (NASDAQ:SLN): FY GAAP EPS of 44.30p. Revenue of £12.41M (+125.6% Y/Y). For further details see: Silence Therapeutics GAAP EPS of 44.30p, revenue of £12.41M
– Positive SLN360 data to be presented in late breaker at the American College of Cardiology (ACC) Annual Meeting on April 3, 2022 – SLN124 phase 1 study in thalassemia now fully enrolled; on-track for topline data in Q3 2022 – SLN124 granted FDA o...
Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (siRNA) therapeutics for the treatment of diseases with significant unmet medical need, today a...
The FDA has granted Silence Therapuetics (SLN -4.1%) Orphan Drug Designation for its short interfering RNA (siRNA) candidate to treat the rare blood disorder polycythemia vera. The candidate, SLN124, already has the designation for thalassemia and myelodysplastic syndrome. In Octobe...
Mark Rothera steps down as President and CEO Silence Therapeutics plc, Nasdaq: SLN (“Silence” or “the Company”), a leader in the discovery, development and delivery of novel short interfering ribonucleic acid (“siRNA”) therapeutics f...
Silence Therapeutics (NASDAQ:SLN) reported positive data from its phase 1 single-ascending dose study of SLN360 in healthy adults with high Lipoprotein, or Lp(a). The company said high Lp(a), defined as ≥ 50 mg/dL, affects ~20% of the world’s population and is a genetic risk fac...
SLN360, an investigational siRNA to reduce risk of Lp(a)-mediated cardiovascular disease, was safe and well tolerated in the study SLN360 significantly lowered Lp(a) in a dose-dependent manner up to 98% with reductions of up to 81% persisting at 150 days Results to be ...
News, Short Squeeze, Breakout and More Instantly...
Silence Therapeutics Plc Company Name:
SLN Stock Symbol:
NASDAQ Market:
Silence Therapeutics Plc Website:
2024-06-28 10:00:07 ET Keay Nakae from Chardan Capital issued a price target of $55.00 for SLN on 2024-06-28 08:03:00. The adjusted price target was set to $55.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $48.33 wi...
2024-06-28 09:00:06 ET Michael Ulz from Morgan Stanley issued a price target of $49.00 for SLN on 2024-06-28 07:44:00. The adjusted price target was set to $49.00. At the time of the announcement, SLN was trading at $19. The overall price target consensus is at $38.00 wi...
Divesiran eliminated the need for phlebotomy in all well-controlled patients following infrequent dosing and was well tolerated Data support advancing divesiran into Phase 2 Company to host conference call today at 8:30am Eastern Time Silence Therapeutics plc (“Si...